Supplement intake test

JRCT ID: jRCTs021180019

Registered date:25/03/2019

Basic Information

• Recruitment status: Complete
• Health condition(s) or Problem(s) studied: Glaucoma, Cataract, Diabetic retinopathy, central serous chorioretinopathy
• Date of first enrollment: 17/05/2018
• Target sample size: 90
• Study type: Interventional
• Intervention(s): Participants take 4 tablets every day (after breakfast and dinner) for 8 weeks

Outcome(s)

• Primary Outcome: Antioxidative potential, BAP level
• Secondary Outcome: oxidative stress, dROMs level, 8OHdG level, blood flow of ONH

Key inclusion & exclusion criteria

• Age minimum: >= 30age old
• Age maximum: <= 75age old
• Gender: Both

Include criteria

1.Patients with glaucoma, cataract, diabetic retinopathy, central serous chorioretinopathy
2.Glaucoma stage: Normal tension glaucoma(in medical treatment eye intraocular pressure less than 16mmHg)
Cataract:Nuclear cataract
Diabetic retinopathy:simple or non proliferative
Central serous chorioretinopathy:all
3.Age:more than 30 years old, less than 75 years old (at entry)
4.BAP:more than 1600umol/L, less than 2200 umol/L
5.dROMs:more than 300CARR
6.BMI:less than 26kg/m2

Exclude criteria

1.Other ophthalmic condition in hospital
2.High myopia
3.LASIK
4.After ophthalmic surgery within three months
5.Cancer patient
6.Autoimmune disease
7.Take a pill
8.other supplements intake
9.other clinical trial
10.allergy
11.pregnant, breast-feeding
12.Patient judged inappropriate by the attending physician

Related Information

• Primary Sponsor: Himori Noriko
• Source(s) of Monetary Support: Wakamoto Pharmaceutical Co.,Ltd
• Secondary ID(s): UMIN000032050